ARCHIVES

Irinotecan And Carboplatin Improve Response In NSCLC

This article is from The Cancer Letter archive.

Vol. 28 No. 6 | June 24, 2005

Download PDF Visit The Full Archive

Related Articles

In Brief: Durant To Leave Alabama, Will Become President, Chief Executive Officer At Fox Chase Cancer Center

September 17, 1982

The Future of Cancer Centers: Demographics Informatics, Genetics, Will BE Major Influences, Robert Young Says

May 7, 1999

FDA Advisors Unanimously Turn Down GPC Biotech’s Orplatna for Prostate Cancer.

July 27, 2007

Avastin Improves PFS Compared To Chemo Alone

January 29, 2010

Computer Learning May Help Women In Treatment Decision

October 30, 2009

NCI’s New Policy On Costly Research

December 10, 1993